Daniel Gaudet, MD, PhD; Denes Pall, MD, PhD; Gerald F. Watts, DSc, PhD, MD; et al.
This randomized clinical trial assesses the safety and effectiveness of plozasiran, an investigational APOC3-targeted drug, in the reduction of serum triglyceride level in patients with severe hypertriglyceridemia.